Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

Core Insights - Dr. Y. Mark Hong has achieved a significant milestone by performing 200 TULSA Procedures™ independently, establishing a new model for MRI-guided prostate therapy [1][2][3] - The TULSA Procedure utilizes Profound Medical's TULSA-PRO system, which is AI-powered and allows for precise ablation of prostate tissue while preserving surrounding structures [2][6] - The TULSA Procedure is a non-invasive treatment option that has shown high success rates, rapid recovery, and minimal complications, positioning it as a potential first-line treatment for prostate cancer [4][7] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, MRI-guided, incision-free therapies for tissue ablation [5] - The TULSA-PRO system combines real-time MRI, AI-enhanced planning, and robotic ultrasound technology, making it a unique offering in the prostate treatment market [6] - Profound is also exploring additional markets for its Sonalleve platform, which is CE marked and FDA approved for various non-invasive treatments [8]